Moreno C, Byrd JC, Hillmen P, et al. Ibrutinib in previously treated chronic lymphocytic leukemia updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 2017, abstract S769.
OS-voordeel met daratumumab-bevattende regimes bij RRMM: POLLUX en CASTOR
jun 2023 | MM